Home Blog Page 19

Rocky Mountain Chocolate Factory, Inc. (NASDAQ:RMCF) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Rocky Mountain Chocolate Factory, Inc. (NASDAQ:RMCF) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02.

About Rocky Mountain Chocolate Factory, Inc. (NASDAQ:RMCF)

Rocky Mountain Chocolate Factory, Inc. is an international franchisor, confectionery manufacturer and retail operator. The Company’s subsidiary, U-Swirl International, Inc. (U-Swirl), franchises and operates soft-serve frozen yogurt stores. The Company operates through five segments: Franchising, Manufacturing, Retail Stores, U-Swirl operations and Other. The Company manufactures a range of chocolate candies and other confectionery products. The Company’s franchised/license system of retail stores features chocolate, frozen yogurt and other confectionary products. The Company also sells its candy in selected locations outside of its system of retail stores and licenses the use of its brand with certain consumer products. The Company’s products include a range of clusters, caramels, creams, mints and truffles. Its individual stores also offer over 15 fudges and other products prepared in the store. The Company uses chocolate, nut meats and other ingredients in its candies.

Story continues below

SPAR Group, Inc. (NASDAQ:SGRP) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

SPAR Group, Inc. (NASDAQ:SGRP) Files An 8-K Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 3.01.         Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing.

Resignation of Audit Committee Members from Board and its Committees

On June 9, 2021, in a letter to the Corporation, all three members of SGRP\’s Audit Committee, namely Mr. Arthur H. Baer, Mr. Igor Novgorodtsev, and Mr. Jeffrey A. Mayer (each a \”Resigning Independent Director\”), resigned from the Corporation\’s Board of Directors (the \”Board\”) and all of its committees, effective immediately (the \”Resignations\”). Management informed Nasdaq of the receipt of the Resignations on June 11, 2021. Please see SGRP\’s Current Report on Form 8-K reporting the Resignation as filed with the SEC on June 14, 2021 (the \”Resignation Report\”), and the Resignation Letter that was attached to the Resignation Report (the \”Resignation Letter\”).

Nasdaq Notice of Failure to Comply with its Board Independence and Audit Committee Composition Rules

As a result of the Resignations, SGRP received a notification letter from Nasdaq dated June 15, 2021 (the \”Nasdaq Deficiency Letter\”), stating that SGRP no longer complies with Nasdaq\’s majority independent director and audit committee requirements as set forth in Nasdaq Listing Rule 5605 (“Nasdaq Rules”).

In the Nasdaq Deficiency Letter, Nasdaq noted that a listed company normally has 45 calendar days to submit a detailed plan to regain compliance for non-compliance with the Nasdaq Rules. However, Nasdaq\’s Staff determined to give a shortened deadline for SGRP to submit its plan to regain compliance, until June 29, 2021, to its discretionary authority set forth in Listing Rule 5101.3. Please see Item 1A — Risk Factors — Risks of a Nasdaq Delisting and Penny Stock Trading in the Amended 2020 Annual Report.

If SGRP\’s plan to regain compliance with the Nasdaq Rules is accepted, Nasdaq\’s Staff can grant an extension of up to 180 calendar days from the date of the Nasdaq Deficiency Letter to permit and evidence such compliance.

The text of the Nasdaq Deficiency Letter is attached to and filed with this Current Report as Exhibit 17.1 hereto and is hereby incorporated by reference into this Current Report and made a part hereof. The descriptions of the Nasdaq Deficiency Letter in this Current Report are subject to and are qualified in their entirety by the full text of the Nasdaq Deficiency Letter.

For background on the ongoing disputes between the Company and its majority stockholders leading to the three independent director resignations, please see the Resignation Report.

Forward Looking Statements

This Current Report on Form 8-K (this \”Current Report\”) contains \”forward-looking statements\” within the \”safe harbor\” provisions of the Private Securities Litigation Reform Act of 1995, made by, or respecting, the Corporation and its subsidiaries (the \”Company\”), and this Current Report has been filed by the Corporation with the SEC. \”Forward-looking statements\” are defined in Section 27A of the Securities Act of 1933, as amended (the \”Securities Act\”), and Section 21E of the Securities Exchange Act of 1934, as amended (the \”Exchange Act\”), and other applicable federal and state securities laws, rules and regulations, as amended (together with the Securities Act and the Exchange Act, \”Securities Laws\”).

All statements (other than those that are purely historical) are forward-looking statements. Words such as \”may,\” \”will,\” \”expect,\” \”intend,\” \”believe,\” \”estimate,\” \”anticipate,\” \”continue,\” \”plan,\” \”project,\” or the negative of these terms or other similar expressions also identify forward-looking statements. Forward-looking statements made by the Corporation in this Current Report may include (without limitation) statements regarding: risks, uncertainties, cautions, circumstances and other factors (\”Risks\”); and plans, intentions, expectations, guidance, the novel coronavirus and COVID-19 pandemic on the Company\’s business, the Corporation\’s compliance with applicable Nasdaq director independence rules, the Company\’s cash flow or financial condition, the Company\’s cash flow, or the pursuit or achievement of the Company\’s corporate objectives.

 

 

You should carefully review and consider the Company\’s forward-looking statements (including all risk factors and other cautions and uncertainties) and other information made, contained or noted in or incorporated by reference into this Current Report, but you should not place undue reliance on any of them. The results, actions, levels of activity, performance, achievements or condition of the Company (including its affiliates, assets, business, clients, capital, cash flow, credit, expenses, financial condition, income, liabilities, liquidity, locations, marketing, operations, performance, prospects, sales, strategies, taxation or other achievement, results, Risks, trends or condition) and other events and circumstances planned, intended, anticipated, estimated or otherwise expected by the Company (collectively, \”Expectations\”), and our forward-looking statements (including all Risks) and other information reflect the Company\’s current views about future events and circumstances. Although the Company believes those Expectations and views are reasonable, the results, actions, levels of activity, performance, achievements or condition of the Company or other events and circumstances may differ materially from our Expectations and views, and they cannot be assured or guaranteed by the Company, since they are subject to Risks and other assumptions, changes in circumstances and unpredictable events (many of which are beyond the Company\’s control). In addition, new Risks arise from time to time, and it is impossible for the Company to predict these matters or how they may arise or affect the Company. Accordingly, the Company cannot assure you that its Expectations will be achieved in whole or in part, that it has identified all potential Risks, or that it can successfully avoid or mitigate such Risks in whole or in part, any of which could be significant and materially adverse to the Company and the value of your investment in the Company\’s common stock.

These forward-looking statements reflect the Company\’s Expectations, views, Risks and assumptions only as of the date of this Current Report, and the Company does not intend, assume any obligation, or promise to publicly update or revise any forward-looking statements (including any Risks or Expectations) or other information (in whole or in part), whether as a result of new information, new or worsening Risks or uncertainties, changed circumstances, future events, recognition, or otherwise.

Item 9.01.         Financial Statements and Exhibits.

(a) Exhibits:
17.1 Text of letter to SPAR Group, Inc. (\”SGRP\”), from the Nasdaq Stock Market, Inc. (\”Nasdaq\”), dated June 15, 2021, stating that SGRP no longer complies with Nasdaq\’s majority independent director and audit committee requirements as set forth in Nasdaq Listing Rule 5605 (as attached hereto and filed herewith).
 
 

SPAR Group, Inc. Exhibit
SEC.gov | Request Rate Threshold Exceeded html {height: 100%} body {height: 100%; margin:0; padding:0;} #header {background-color:#003968; color:#fff; padding:15px 20px 10px 20px;font-family:Arial,…
To view the full exhibit click here

About SPAR Group, Inc. (NASDAQ:SGRP)

Spar Group, Inc. is an international merchandising and marketing services company. The Company provides its merchandising and other marketing services to manufacturers, distributors and retailers across the world, primarily in mass merchandisers, office supply, grocery, drug store, independent, convenience, toy, home improvement and electronics stores. It operates through two segments: the Domestic Division and the International Division. The Domestic Division provides merchandising and marketing services, furniture and other product assembly services, audit services, and technology services to manufacturers, distributors and retailers in the United States. Those services are primarily performed in mass merchandisers, office supply, grocery, drug store, dollar and electronics stores. The International Division provides merchandising, marketing services and in-store event staffing through subsidiaries in Japan, Canada, South Africa, India, China, Australia, Mexico and Turkey.

Story continues below

VITALITY BIOPHARMA, INC. (OTCMKTS:VBIO) Files An 8-K Other Events

VITALITY BIOPHARMA, INC. (OTCMKTS:VBIO) Files An 8-K Other Events
Item 8.01

On June 21, 2021, Vitality Biopharma, Inc. (the “Company”) posted on the Company’s website (www.vitality.bio) a letter from the Company’s Chief Executive Officer, Michael Cavanaugh, to the Company’s shareholders. A copy of the letter is filed as Exhibit 20.1 to this Current Report on Form 8-K.

20.1 Letter from Michael Cavanaugh to the Company’s Shareholders


Vitality Biopharma, Inc. Exhibit
EX-20.1 2 ex20-1.htm   Exhibit 20.1     To the Shareholders of Vitality Biopharma,…
To view the full exhibit click here

About VITALITY BIOPHARMA, INC. (OTCMKTS:VBIO)

Vitality Biopharma, Inc., formerly Stevia First Corp., is engaged in the development of cannabinoid prodrug pharmaceuticals. The Company unlocks the power of cannabinoids for the treatment of serious neurological and inflammatory disorders. Its product pipeline includes cannabosides, VITA-100 and VITA-210. Cannabosides are cannabinoid glycoside prodrugs. VITA-100 is an oral cannabinoid formulation containing cannabosides that is being developed for treatment of inflammatory bowel disease, epilepsy, schizophrenia, and other disorders. VITA-210 is a cannabinoid glycoside prodrug being developed primarily for treatment of pain and muscle spasticity in multiple sclerosis and in rare white matter disorders. The Company’s facilities include laboratories and a manufacturing suite for good manufacturing practices (GMPs) production, which will be used for pharmaceutical-grade production of products to be tested in clinical trials.

Story continues below

TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure

TONIX PHARMACEUTICALS HOLDING CORP. (NASDAQ:TNXP) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

Tonix Pharmaceuticals Holding Corp. (the “Company”) updated its investor presentations, which are used to conduct meetings with investors, stockholders and analysts and at investor conferences, and which the Company intends to place on its website, which may contain nonpublic information. Copies of the presentations are filed as Exhibits 99.01 and 99.02 hereto and incorporated herein by reference.  

The information in this Item 7.01 of this Current Report on Form 8-K, including Exhibits 99.01 and 99.02 attached hereto, shall not be deemed “filed” for purposes of Section 18 of the United States Securities Exchange Act of 1934 (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the United States Securities Act of 1933 or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 9.01 Financial Statements and Exhibits.

99.01 Corporate Presentation by the Company for June 2021
99.02 Abbreviated Corporate Presentation by the Company for June 2021


Tonix Pharmaceuticals Holding Corp. Exhibit
EX-99.01 2 ex99-01.htm CORPORATE PRESENTATION   Tonix Pharmaceuticals Holding Corp. 8-K   Exhibit 99.01     © 2021 Tonix Pharmaceuticals Holding Corp. 1 June 2021 Version P0304 6 – 22 – 2021 (Doc 0852) Investor Presentation NASDAQ:TNXP     © 2021 Tonix Pharmaceuticals Holding Corp. 2 Cautionary Note on Forward – Looking Statements Certain statements in this presentation regarding strategic plans,…
To view the full exhibit click here

Story continues below

BIOCARDIA, INC. (OTCMKTS:BCDA) Files An 8-K Other Events

BIOCARDIA, INC. (OTCMKTS:BCDA) Files An 8-K Other Events
Item 8.01 Other Events.

On June 22, 2021, BioCardia, Inc. (the “Company”) issued a press release announcing that data demonstrating the high CD34+ cell dosing being achieved in the ongoing pivotal CardiAMP Heart Failure Trial will be presented at the virtual European Society of Cardiology Heart Failure Annual Meeting 2021. A copy of the press release is attached hereto as Exhibit 99.1 to this current report on Form 8-K and is incorporated herein by reference.

Item 9.01   Financial Statements and Exhibits.

(d) Exhibits

 
 

BioCardia, Inc. Exhibit
EX-99.1 2 ex_258884.htm EXHIBIT 99.1 ex_258884.htm   Exhibit 99.1     FOR IMMEDIATE RELEASE     BioCardia to Present CardiAMP Cell Therapy Clinical Trial Data at European Society of Cardiology Heart Failure 2021   Cell Therapy Platform Demonstrates High Dose CD34+ Cell Performance Characteristics in Patients with Ischemic Heart Failure.   June 22,…
To view the full exhibit click here

About BIOCARDIA, INC. (OTCMKTS:BCDA)

BioCardia, Inc., formerly Tiger X Medical, Inc., is a clinical-stage regenerative medicine company. The Company is engaged in developing therapeutics for cardiovascular diseases. The Company’s lead therapeutic candidate is the CardiAMP Cell Therapy System (CardiAMP). It focuses on the Phase III trial for CardiAMP in ischemic systolic heart failure. The Company also offers CardiALLO Cell Therapy System (CardiALLO), an allogeneic off the shelf mesenchymal stem cell product candidate from other donors. It focuses on the Phase II trial for CardiALLO for the treatment of ischemic systolic heart failure. The Company focuses on various fields of autologous and allogeneic cell-based therapies to manage the lives of patients with cardiovascular conditions. CardiAMP is a therapeutic treatment that includes a companion diagnostic. It consists of a cell potency screening test, a point of care cell processing platform and a biotherapeutic delivery system.

Story continues below

PHARMACYTE BIOTECH, INC. (OTCMKTS:PMCB) Files An 8-K Other Events

PHARMACYTE BIOTECH, INC. (OTCMKTS:PMCB) Files An 8-K Other Events
Item 8.01 Other Events.

On June 18, 2021, PharmaCyte Biotech, Inc. (“PharmaCyte”) announced that its Annual Meeting of Stockholders, held virtually on Wednesday, June 16, 2021, has been adjourned until Wednesday, June 30, 2021, at 11:00 A.M. PDT in order to allow additional time for stockholders to vote on Proposal No. 2, the proposal to increase the authorized number of shares of capital stock. When the annual meeting is reconvened on June 30, 2021, it will continue to be held virtually at https://www.virtualshareholdermeeting.com/PMCB2021. A copy of the press release is attached as Exhibit 99.1 herein.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 


PharmaCyte Biotech, Inc. Exhibit
EX-99.1 2 pharmacyte_8k-ex9901.htm PRESS RELEASE: PHARMACYTE BIOTECH ANNOUNCES ADJOURNMENT OF ANNUAL MEETING OF SHAREHOLDERS,…
To view the full exhibit click here

About PHARMACYTE BIOTECH, INC. (OTCMKTS:PMCB)

PharmaCyte Biotech, Inc., formerly Nuvilex, Inc., is a clinical-stage biotechnology company focused on developing and preparing to commercialize treatments for cancer and diabetes based upon a cellulose-based live cell encapsulation technology known as Cell-in-a-Box. The Company’s Cell-in-a-Box technology will be used as a platform upon which treatments for various types of cancer, including advanced, inoperable pancreatic cancer, and diabetes will be developed. The Company is developing therapies for pancreatic and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of the cancer. It is also developing a therapy for Type I diabetes and insulin-dependent Type II diabetes based upon the encapsulation of a human cell line genetically engineered to produce, store and secrete insulin at levels in proportion to the levels of blood sugar in the human body using its Cell-in-a-Box technology.

Story continues below

ACASTI PHARMA INC. (NASDAQ:ACST) Files An 8-K Results of Operations and Financial Condition

ACASTI PHARMA INC. (NASDAQ:ACST) Files An 8-K Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits

99.1 Press Release issued by Acasti Pharma Inc. on June 22, 2021

Acasti Pharma Inc. Exhibit
EX-99.1 2 exh_991.htm PRESS RELEASE EdgarFilingEXHIBIT 99.1 Acasti Pharma Provides Fiscal 2021 Year-End Business UpdateUpdate on Acquisition of Grace Therapeutics and Strategic Plans for CaPre LAVAL,…
To view the full exhibit click here

About ACASTI PHARMA INC. (NASDAQ:ACST)

Acasti Pharma Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in developing, clinically studying and marketing new pharmaceutical products to treat human cardiovascular conditions. The Company is involved in the development and commercialization of pharmaceutical applications of its licensed rights for cardiovascular diseases. The Company’s prescription drug candidate is CaPre, which is being developed for the treatment of severe hypertriglyceridemia and eventually mild to moderate hypertriglyceridemia. The Company’s ONEMIA has a natural health product status in Canada, and it is commercialized as a medical food in the United States. Onemia is a purified omega-3 phospholipids concentrate derived from krill oil with lower levels of phospholipids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) content than CaPre.

Story continues below

Digipath, Inc. (OTCMKTS:DIGP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

Digipath, Inc. (OTCMKTS:DIGP) Files An 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 18, 2021, Todd Peterson resigned from his positions as Chief Financial Officer, Secretary and Treasurer of Digipath, Inc. (the “Company”), effective June 18, 2021.

Story continues below

Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Other Events

Tyme Technologies, Inc. (OTCMKTS:TYMI) Files An 8-K Other Events
Item 8.01 Other Events.


About Tyme Technologies, Inc. (OTCMKTS:TYMI)

Tyme Technologies, Inc., formerly Global Group Enterprises Corp., conducts majority of its research and development activities and other business operations, through its subsidiary, Tyme Inc. (Tyme). Tyme is a clinical-stage biopharmaceutical company. Tyme is focused on the development and commercialization of highly targeted cancer therapeutics with a range of oncology indications. The Company’s another subsidiary, Luminant Biosciences, LLC, conducts the initial research and development of the Company’s therapeutic platform. The Company is formulating its regulatory and drug development program for its lead drug candidate, SM-88, and working towards the initiation of its Phase II clinical trial. The Company is also evaluating the expansion of its Phase II program to other types of cancer. The Company has not generated any revenue.

Story continues below

SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Other Events

SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES) Files An 8-K Other Events
Item 8.01

On June 18, 2021, Second Sight Medical Products, Inc. (“the Company”) posted an updated corporate deck which can be found on the Company’s website at https://investors.secondsight.com/events/event-details/eyes-corporate-investor-deck-june-2021.

About SECOND SIGHT MEDICAL PRODUCTS, INC. (NASDAQ:EYES)

Second Sight Medical Products, Inc. is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight. It does not restore normal vision and it does not slow or reverse the progression of the disease. The Company’s Argus II System employs electrical stimulation to bypass degenerated photoreceptor cells and to stimulate remaining viable retinal cells thereby inducing visual perception in blind individuals. The Argus II System works by converting video images captured by a miniature camera housed in a patient’s glasses into a series of small electrical pulses that are transmitted wirelessly to an array of electrodes that are implanted on the surface of the retina.

Story continues below